Cellectis S.A. Overview
Pro stress-test →Cellectis is a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies. The company utilizes its proprietary TALEN (Transcription Activator-Like Effector Nucleases) technology to engineer innovative cell therapies and aims to harness the power of the immune system to identify and destroy cancer cells more effectively.
Strategic Profile
Pro stress-test →Cellectis transitioned in 2025 to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel. Lasme-cel demonstrated a potentially transformative efficacy profile in one of oncology's most challenging settings, achieving 100% overall response rate in the target Phase 2 population, critically converting all patients in the target population into transplant-eligible candidates.
Competitive Landscape
Pro stress-test →Cellectis competes in the allogeneic CAR-T immunotherapy space against companies like Allogene Therapeutics (cema-cel/UCART19 partnership history), Juno Therapeutics, and other CAR-T developers. Key differentiation is the TALEN gene-editing platform enabling off-the-shelf cell therapies. Strategic partnership with AstraZeneca provides collaboration revenue and development support.
Industry Context
Cellectis S.A. operates in Gene Therapy / Cell Immunotherapy.
Key facts
Founded: 2007 · Headquarters: Paris, France · Employees: N/A · Revenue: $7.5M (Q1 2026) · Market cap: N/A